Cyclerion Therapeutics and Korsana Biosciences announced a definitive merger agreement in an all-stock transaction that will result in the combined company operating under the Korsana Biosciences name and trading on Nasdaq under the ticker symbol KRSA.
The deal is supported by an oversubscribed private financing expected to generate approximately $380 million in gross proceeds. The investment syndicate includes major healthcare and institutional investors such as Fairmount, Venrock Healthcare Capital Partners, General Atlantic, Wellington Management, RA Capital Management, and others. The financing is expected to close immediately prior to the merger and provide sufficient capital to fund operations into 2029.
Following completion of the transaction, existing Korsana shareholders are expected to own approximately 98.5% of the combined company, while Cyclerion shareholders will hold about 1.5%, subject to adjustments based on Cyclerion’s net cash at closing.
The combined company will focus on advancing Korsana’s pipeline of therapies for neurodegenerative diseases, led by its primary program KRSA-028, a next-generation monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease. The therapy leverages Korsana’s proprietary THETA platform, designed to improve delivery across the blood-brain barrier and enhance safety and efficacy compared to earlier approaches.
KRSA-028 is expected to enter clinical development with Phase 1 healthy volunteer data anticipated in mid-2027, followed by interim proof-of-concept data in Alzheimer’s patients by the end of 2027. The broader pipeline includes additional undisclosed programs targeting neurodegenerative conditions.
The merged company will be led by Korsana’s current leadership team, including CEO Jonathan Violin, Ph.D., and its existing board of directors. The transaction has been approved by both companies’ boards and is expected to close in the third quarter of 2026, subject to shareholder approvals and customary regulatory conditions.
Cyclerion stated that the transaction follows a comprehensive strategic review and represents the best path forward for its shareholders, while enabling participation in Korsana’s pipeline and future growth potential.
KEY QUOTES:
“Korsana is determined to deliver breakthrough medicines for patients suffering from neurodegenerative disorders. With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies. Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s disease. We are also building a broader pipeline leveraging our proprietary platform to target other devastating neurodegenerative disorders.”
Jonathan Violin, Ph.D., President And Chief Executive Officer, Korsana Biosciences
“Our transaction with Korsana is the result of a comprehensive strategic review, and we believe it represents the best path forward for Cyclerion. Korsana’s promising and innovative pipeline targeting neurodegenerative disorders, beginning with Alzheimer’s disease, provides the potential for significant value creation for Cyclerion’s shareholders.”
Regina Graul, Ph.D., President And Chief Executive Officer, Cyclerion Therapeutics
